Conversion Right Triggered for LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C., Oct 06, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America (R) Holdings (LabCorp (R) ) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below.

LabCorp To Offer a New Companion Diagnostic for Non-Small Cell Lung Cancer

BURLINGTON, N.C., Oct 03, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America (R) Holdings (LabCorp (R) ) (NYSE: LH) announced today the nationwide availability of a new FDA-approved companion diagnostic for lung cancer patients. The drug XALKORI (R) , available from Pfizer, and Abbott

LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest

BURLINGTON, N.C., Sep 13, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America (R) Holdings (LabCorp (R) ) (NYSE: LH) announced today that for the period of September 12, 2011 to March 11, 2012, its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the

LabCorp to Offer a New Companion Diagnostic for Melanoma

BURLINGTON, N.C., Sep 12, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America (R) Holdings (LabCorp (R) ) (NYSE: LH) announced today the nationwide availability of a new FDA-approved diagnostic for melanoma patients. The drug Zelboraf TM and the cobas(R) 4800 BRAF V600 Mutation Test companion

Laboratory Corporation of America(R) Holdings Announces Results of Offer to Purchase Its Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C., Sep 12, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America (R) Holdings (LabCorp (R) ) (NYSE: LH) announced today the results of its offer (the "Offer") to purchase its Zero Coupon Convertible Subordinated Notes due 2021 (the "Notes") for cash.

LabCorp Extends Tender Offer for All Outstanding Shares of Orchid Cellmark Inc.

BURLINGTON, N.C., Sep 12, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America(R) Holdings (NYSE: LH) today announced that LabCorp is extending until 5:00 p.m., New York City time, on October 7, 2011 LabCorp's previously announced cash tender offer for all outstanding shares of the common

LabCorp Extends Agreement with UnitedHealthcare

BURLINGTON, N.C., Sep 08, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America (R) Holdings (LabCorp (R) ) (NYSE: LH) announced today that it has extended the term of its agreement with UnitedHealthcare Insurance Company (UnitedHealthcare), an affiliate of UnitedHealth Group Incorporated

LabCorp is Scheduled to Present at the Bank of America Merrill Lynch Global Healthcare Conference

BURLINGTON, N.C., Sep 06, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America (R) Holdings (LabCorp (R) ) (NYSE: LH) today announced that David P. King, Chairman and Chief Executive Officer, is scheduled to speak at the Bank of America Merrill Lynch Global Healthcare Conference in London,

LabCorp Introduces HCV Resistance Testing through Monogram Biosciences with the Launch of HCV GenoSure(R) NS3/4A

BURLINGTON, N.C., Aug 25, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America (R) Holdings (LabCorp (R) ) (NYSE: LH) announced today the nationwide availability of a nucleic acid sequencing assay that reports NS3 and NS4A mutations and NS3 associated resistance to the recently approved

LabCorp Extends Tender Offer for All Outstanding Shares of Orchid Cellmark Inc.

BURLINGTON, N.C., Aug 15, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America(R) Holdings (NYSE: LH) today announced that LabCorp is extending until 5:00 p.m., New York City time, on September 9, 2011 LabCorp's previously announced cash tender offer for all outstanding shares of the common